Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Investor Day (2016)
16 slides from Coloplast A/s Class B's investor day presentation, 2016
Slide 1: Chronic Care Update
Chronic Care Update Coloplast Capital Markets Day 2016 Kristian Villumsen, EVP Chronic Care
Slide 2: Chronic Care represents the majority of Coloplast sales and has a #1 global position
Chronic Care represents the majority of Coloplast sales and has a #1 global position Chronic Care sales, in DKK Chronic Care sales in DKK by business area FY 14/15 >75% FY 14/15 of Coloplast sales 10.6 Ostomy Care Continence Care billion of DKK Chronic Care sales in DKK by region annual sales FY 14/
Slide 3: We deliver consistent and winning growth rates across our regions
We deliver consistent and winning growth rates across our regions Chronic Care sales growth vs. market by region, % FY 12/13 – FY 14/15 Region Europe Other Developed Markets Emerging Markets Market growth Coloplast growth Market growth Coloplast growth Market growth Coloplast growth 12/13 13/14 14/1
Slide 4: We see four major trends affecting our industry
We see four major trends affecting our industry Rise of the healthcare consumer Increasingly Cost pressure and consolidated and demand for value Industry sophisticated from payers channels Digitalization of healthcare information Page 4
Slide 5: In this space, we're building a consumer healthcare company
In this space, we’re building a consumer healthcare company, which is all about clinical and consumer preference Superior and clinically differentiated products A unique commercial model SenSura® Mio Convex + SpeediCath® Compact Eve Page 5
Slide 6: Our ambition is to outgrow the market through three initiatives
Our ambition is to outgrow the market through three initiatives Our revenue ambition is to outgrow the market Our strategic themes 1 5% - 6% 4% - 5% 2 3 Market growth Annual Page 6
Slide 7: Our new SenSura Mio and Brava platform has increased our Ostomy Care growth momentum
1 Superior products Our new SenSura® Mio and Brava® platform has increased our Ostomy Care growth momentum over the past 6 quarters We are rolling out our new SenSura® Mio and Brava® platform Ostomy Care sales growth, % Q1 14/15 – Q2 15/16 % 9 8 7 6 5 4 3 2 1 Building a strong BodyFit® position that
Slide 8: We have a strong portfolio of continence products and a clear value proposition
1 Superior products We have a strong portfolio of continence products and a clear value proposition – growth impacted by US and Saudi Arabia Innovative product portfolio Continence Care sales growth, % Q1 14/15 – Q2 15/16 % 10 9 8 7 6 5 4 3 2 SpeediCath® SpeediCath® SpeediCath® 1 Compact Eve Compact
Slide 9: Three initiatives to drive Continence Care growth and mitigate SpeediCath patent expiration
1 Superior products We are focusing on three initiatives to drive Continence Care growth and mitigate SpeediCath® patent expiration We drive growth through three initiatives We believe patent exposure is limited Patent expiry September 2017 Invest in new innovation Exposure in tender markets: DK SE
Slide 10: CARE helps us increase retention and improve product compliance
2 Unique consumer relationship CARE helps us increase retention and improve product compliance for more than 400,000 enrolled consumers We co-develop Care content with Care is a personal and “high-touch” Global program with shared local clinicians program infrastructure Advisors available on phone C
Slide 11: With our DtC marketing program we reach into the community
2 Unique consumer relationship With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page
Slide 12: We invest to pursue growth opportunities and monitor previous investments
3 Next level frontline execution We invest to pursue growth opportunities and monitor previous investments, recalibrating if needed We are executing on our mature markets investments We are recalibrating some investments to new realities Expansion in Breakthrough in Expansion in Expansion in Expansi
Slide 13: Expansion in China is a unique growth opportunity
3 Next level frontline execution Expansion in China is a unique growth opportunity - we are currently facing challenges and mitigating them Original investment thesis Challenges and how we are mitigating them Challenge Mitigation Slowdown in market Paused investments and focusing on optimizing curre
Slide 14: New intermittent catheter opportunities in Japan and Australia
3 Next level frontline execution We have been able to open up new intermittent catheter opportunities in Japan and Australia Opportunity Improved Continence Care reimbursement Continence Care patients impacted When From: Partly coverage of reusable/some Japan disposable products 1 = 100,000 Q3 15/16
Slide 15: Our ambition is to outgrow the market through 3 initiatives
Our ambition is to outgrow the market through 3 initiatives Our revenue ambition is to outgrow the market Our strategic themes 5% - 6% 4% - 5% Market growth Annual organic Page 15
Slide 16: Page 16 May 2016 Corporate Visual Identity-Brand Communication Platform
Page 16 May 2016 Corporate Visual Identity-Brand Communication Platform